Rheumatoid arthritis, anti-cyclic citrullinated peptide positivity, and cardiovascular disease risk in the women's health initiative

Arthritis and Rheumatology

Volumn 67, Issue 9, 2015, Pages 2311-2322

  MacKey, Rachel H ^a   Kuller, Lewis H ^a   Deane, Kevin D ^b   Walitt, Brian T ^c   Chang, Yue Fang ^a   Holers, V Michael ^b   Robinson, William H ^d,e   Tracy, Russell P ^f   Hlatky, Mark A ^d   Eaton, Charles B ^g   Liu, Simin ^g   Freiberg, Matthew S ^h   Talabi, Mehret Birru ^a   Schelbert, Erik B ^a   Moreland, Larry W ^a  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c WASHINGTON HOSPITAL CENTER   (United States)

^d STANFORD UNIVERSITY   (United States)

^e VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^f UNIVERSITY OF VERMONT   (United States)

^g BROWN UNIVERSITY   (United States)

^h VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; AZATHIOPRINE; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; CYCLOPHOSPHAMIDE; CYCLOSPORIN; GOLD; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; MINOCYCLINE; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE; AUTOANTIBODY; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE; IL6 PROTEIN, HUMAN; INTERLEUKIN 6;

ADULT; ARTHRALGIA; ARTICLE; BLOOD CELL COUNT; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DIABETES MELLITUS; DISEASE SEVERITY; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MORBIDITY; OBSERVATIONAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK FACTOR; SELF REPORT; SMOKING; WAIST CIRCUMFERENCE; WOMEN'S HEALTH; AGED; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; COHORT ANALYSIS; CORONARY DISEASE; HYPERCHOLESTEROLEMIA; HYPERTENSION; IMMUNOLOGY; INCIDENCE; LEUKOCYTE COUNT; MIDDLE AGED; PROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; STROKE; UNITED STATES;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; CARDIOVASCULAR DISEASES; COHORT STUDIES; CORONARY DISEASE; DIABETES MELLITUS; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; INCIDENCE; INTERLEUKIN-6; LEUKOCYTE COUNT; MIDDLE AGED; PEPTIDES, CYCLIC; POSTMENOPAUSE; PROSPECTIVE STUDIES; RHEUMATOID FACTOR; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SMOKING; STROKE; UNITED STATES;

EID: 84940116967     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39198     Document Type: Article

References (49)

1. Meune C, Touze E, Trinquart L, Allanore Y., High risk of clinical cardiovascular events in rheumatoid arthritis: levels of associations of myocardial infarction and stroke through a systematic review and meta-analysis. Arch Cardiovasc Dis 2010; 103: 253-61.
2. Avina-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D., Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008; 59: 1690-7.
3. Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, et al., Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003; 107: 1303-7.
4. Bergstrom U, Jacobsson LT, Turesson C., Cardiovascular morbidity and mortality remain similar in two cohorts of patients with long-standing rheumatoid arthritis seen in 1978 and 1995 in Malmo, Sweden. Rheumatology (Oxford) 2009; 48: 1600-5.
5. Boyer JF, Gourraud PA, Cantagrel A, Davignon JL, Constantin A., Traditional cardiovascular risk factors in rheumatoid arthritis: a meta-analysis. Joint Bone Spine 2011; 78: 179-83.
6. Solomon DH, Curhan GC, Rimm EB, Cannuscio CC, Karlson EW., Cardiovascular risk factors in women with and without rheumatoid arthritis. Arthritis Rheum 2004; 50: 3444-9.
7. Maradit Kremers H, Crowson CS, Therneau TM, Roger VL, Gabriel SE., High ten-year risk of cardiovascular disease in newly diagnosed rheumatoid arthritis patients: a population-based cohort study. Arthritis Rheum 2008; 58: 2268-74.
8. Solomon DH, Kremer J, Curtis JR, Hochberg MC, Reed G, Tsao P, et al., Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Ann Rheum Dis 2010; 69: 1920-5.
9. Del Rincon I, Freeman GL, Haas RW, O'Leary DH, Escalante A., Relative contribution of cardiovascular risk factors and rheumatoid arthritis clinical manifestations to atherosclerosis. Arthritis Rheum 2005; 52: 3413-23.
10. Farragher TM, Lunt M, Bunn DK, Silman AJ, Symmons DP., Early functional disability predicts both all-cause and cardiovascular mortality in people with inflammatory polyarthritis: results from the Norfolk Arthritis Register. Ann Rheum Dis 2007; 66: 486-92.
11. Metsios GS, Stavropoulos-Kalinoglou A, Panoulas VF, Wilson M, Nevill AM, Koutedakis Y, et al., Association of physical inactivity with increased cardiovascular risk in patients with rheumatoid arthritis. Eur J Cardiovasc Prev Rehabil 2009; 16: 188-94.
12. Whiting PF, Smidt N, Sterne JA, Harbord R, Burton A, Burke M, et al., Systematic review: accuracy of anti-citrullinated peptide antibodies for diagnosing rheumatoid arthritis. Ann Intern Med 2010; 152: 456-64.
13. Kuller LH, Mackey RH, Walitt BT, Deane KD, Holers VM, Robinson WH, et al., Rheumatoid arthritis in the Women's Health Initiative: methods and baseline evaluation. Am J Epidemiol 2014; 179: 917-26.
14. Kuller LH, Mackey RH, Walitt BT, Deane KD, Holers VM, Robinson WH, et al., Determinants of mortality among postmenopausal women in the Women's Health Initiative who report rheumatoid arthritis. Arthritis Rheumatol 2014; 66: 497-507.
15. Peters MJ, Symmons DP, McCarey D, Dijkmans BA, Nicola P, Kvien TK, et al., EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010; 69: 325-31.
16. Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials 1998; 19: 61-109.
17. Lynch CP, McTigue KM, Bost JE, Tinker LF, Vitolins M, Adams-Campbell L, et al., Excess weight and physical health-related quality of life in postmenopausal women of diverse racial/ethnic backgrounds. J Womens Health (Larchmt) 2010; 19: 1449-58.
18. McTigue KM, Chang YF, Eaton C, Garcia L, Johnson KC, Lewis CE, et al., Severe obesity, heart disease, and death among white, African American, and Hispanic postmenopausal women. Obesity (Silver Spring) 2014; 22: 801-10.
19. Margolis KL, Manson JE, Greenland P, Rodabough RJ, Bray PF, Safford M, et al., Leukocyte count as a predictor of cardiovascular events and mortality in postmenopausal women: the Women's Health Initiative Observational Study. Arch Intern Med 2005; 165: 500-8.
20. Curb JD, McTiernan A, Heckbert SR, Kooperberg C, Stanford J, Nevitt M, et al, for the WHI Morbidity and Mortality Committee. Outcomes ascertainment and adjudication methods in the Women's Health Initiative. Ann Epidemiol 2003; 13: S122-8.
21. Ng J, Hurley CK, Baxter-Lowe LA, Chopek M, Coppo PA, Hegland J, et al., Large-scale oligonucleotide typing for HLA-DRB1/3/4 and HLA-DQB1 is highly accurate, specific, and reliable. Tissue Antigens 1993; 42: 473-9.
22. Chandra PE, Sokolove J, Hipp BG, Lindstrom TM, Elder JT, Reveille JD, et al., Novel multiplex technology for diagnostic characterization of rheumatoid arthritis. Arthritis Res Ther 2011; 13: R102.
23. Walitt B, Mackey R, Kuller L, Deane KD, Robinson W, Holers VM, et al., Predictive value of autoantibody testing for validating self-reported diagnoses of rheumatoid arthritis in the Women's Health Initiative. Am J Epidemiol 2013; 177: 887-93.
24. Walitt BT, Constantinescu F, Katz JD, Weinstein A, Wang H, Hernandez RK, et al., Validation of self-report of rheumatoid arthritis and systemic lupus erythematosus: the Women's Health Initiative. J Rheumatol 2008; 35: 811-8.
25. Lopez-Longo FJ, Oliver-Minarro D, de la Torre I, Gonzalez-Diaz de Rabago E, Sanchez-Ramon S, Rodriguez-Mahou M, et al., Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis. Arthritis Rheum 2009; 61: 419-24.
26. Liang KP, Maradit Kremers H, Crowson CS, Snyder MR, Therneau TM, Roger VL, et al., Autoantibodies and the risk of cardiovascular events. J Rheumatol 2009; 36: 2462-9.
27. Humphreys JH, van Nies J, Chipping J, Marshall T, Mil A, Symmons D, et al., Rheumatoid factor and anti-citrullinated protein antibody positivity, but not level, are associated with increased mortality in patients with rheumatoid arthritis: results from two large independent cohorts. Arthritis Res Ther 2014; 16: 483.
28. Innala L, Moller B, Ljung L, Magnusson S, Smedby T, Sodergren A, et al., Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: a five year prospective study. Arthritis Res Ther 2011; 13: R131.
29. McCoy SS, Crowson CS, Maradit-Kremers H, Therneau TM, Roger VL, Matteson EL, et al., Longterm outcomes and treatment after myocardial infarction in patients with rheumatoid arthritis. J Rheumatol 2013; 40: 605-10.
30. Sokolove J, Brennan MJ, Sharpe O, Lahey LJ, Kao AH, Krishnan E, et al., Citrullination within the atherosclerotic plaque: a potential target for the anti-citrullinated protein antibody response in rheumatoid arthritis. Arthritis Rheum 2013; 65: 1719-24.
31. Karpouzas GA, Malpeso J, Choi TY, Li D, Munoz S, Budoff MJ., Prevalence, extent and composition of coronary plaque in patients with rheumatoid arthritis without symptoms or prior diagnosis of coronary artery disease. Ann Rheum Dis 2014; 73: 1797-804.
32. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, et al, for the INSIGHT SMART Study Group. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5: e203.
33. Duprez DA, Neuhaus J, Kuller LH, Tracy R, Belloso W, De Wit S, et al, for the INSIGHT SMART Study Group. Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One 2012; 7: e44454.
34. Maradit-Kremers H, Crowson CS, Nicola PJ, Ballman KV, Roger VL, Jacobsen SJ, et al., Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2005; 52: 402-11.
35. Lertnawapan R, Bian A, Rho YH, Kawai VK, Raggi P, Oeser A, et al., Cystatin C, renal function, and atherosclerosis in rheumatoid arthritis. J Rheumatol 2011; 38: 2297-300.
36. Schelbert EB, Cao JJ, Sigurdsson S, Aspelund T, Kellman P, Aletras AH, et al., Prevalence and prognosis of unrecognized myocardial infarction determined by cardiac magnetic resonance in older adults. JAMA 2012; 308: 890-6.
37. Giles JT, Malayeri AA, Fernandes V, Post W, Blumenthal RS, Bluemke D, et al., Left ventricular structure and function in patients with rheumatoid arthritis, as assessed by cardiac magnetic resonance imaging. Arthritis Rheum 2010; 62: 940-51.
38. Crowson CS, Nicola PJ, Maradit Kremers H, O'Fallon WM, Therneau TM, Jacobsen SJ, et al., How much of the increased incidence of heart failure in rheumatoid arthritis is attributable to traditional cardiovascular risk factors and ischemic heart disease? Arthritis Rheum 2005; 52: 3039-44.
39. Myasoedova E, Davis JM III, Crowson CS, Roger VL, Karon BL, Borgeson DD, et al., Rheumatoid arthritis is associated with left ventricular concentric remodeling: results of a population-based cross-sectional study. Arthritis Rheum 2013; 65: 1713-8.
40. Kobayashi Y, Giles JT, Hirano M, Yokoe I, Nakajima Y, Bathon JM, et al., Assessment of myocardial abnormalities in rheumatoid arthritis using a comprehensive cardiac magnetic resonance approach: a pilot study. Arthritis Res Ther 2010; 12: R171.
41. Yin Y, Liang D, Zhao L, Li Y, Liu W, Ren Y, et al., Anti-cyclic citrullinated peptide antibody is associated with interstitial lung disease in patients with rheumatoid arthritis. PLoS One 2014; 9: e92449.
42. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL., Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
43. Myasoedova E, Chandran A, Ilhan B, Major BT, Michet CJ, Matteson EL, et al., The role of rheumatoid arthritis (RA) flare and cumulative burden of RA severity in the risk of cardiovascular disease. Ann Rheum Dis 2015. E-pub ahead of print.
44. Rao VU, Pavlov A, Klearman M, Musselman D, Giles JT, Bathon JM, et al., An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy. Arthritis Rheumatol 2015; 67: 372-80.
45. Akkara Veetil BM, Myasoedova E, Matteson EL, Gabriel SE, Crowson CS., Use of lipid-lowering agents in rheumatoid arthritis: a population-based cohort study. J Rheumatol 2013; 40: 1082-8.
46. Micha R, Imamura F, Wyler von Ballmoos M, Solomon DH, Hernan MA, Ridker PM, et al., Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol 2011; 108: 1362-70.
47. Chung CP, Oeser A, Avalos I, Gebretsadik T, Shintani A, Raggi P, et al., Utility of the Framingham risk score to predict the presence of coronary atherosclerosis in patients with rheumatoid arthritis. Arthritis Res Ther 2006; 8: R186.
48. Peters MJ, van Halm VP, Voskuyl AE, Smulders YM, Boers M, Lems WF, et al., Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis Rheum 2009; 61: 1571-9.
49. Gomez-Vaquero C, Robustillo M, Narvaez J, Rodriguez-Moreno J, Gonzalez-Juanatey C, Llorca J, et al., Assessment of cardiovascular risk in rheumatoid arthritis: impact of the new EULAR recommendations on the score cardiovascular risk index. Clin Rheumatol 2012; 31: 35-9.